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Abstract
Background: Influenza and pertussis vaccines have been recommended in Australia for women during each
pregnancy since 2010 and 2015, respectively. Estimating vaccination coverage and identifying factors affecting
uptake are important for improving antenatal immunisation services.
Methods: A random sample of 800 Western Australian women ≥18 years of age who gave birth between 4th April
and 4th October 2015 were selected. Of the 454 (57%) who were contactable by telephone, 424 (93%) completed a
survey. Data were weighted by maternal age and area of residence to ensure representativeness. The proportion
immunised against influenza and pertussis was the main outcome measure; multivariate logistic regression was
used to identify factors significantly associated with antenatal vaccination. Results from the 2015 study were
compared to similar surveys conducted in 2012–2014.
Results: In 2015, 71% (95% CI 66–75) of women received pertussis-containing vaccine and 61% (95% CI 56–66)
received influenza vaccine during pregnancy; antenatal influenza vaccine coverage was 18% higher than in 2014
(43%; 95% CI: 34–46). Pertussis and influenza vaccine were co-administered for 68% of the women who received
both vaccines. The majority of influenza vaccinations in 2015 were administered during the third trimester of pregnancy,
instead of the second trimester, as was observed in prior years. Women whose care provider recommended both
antenatal vaccinations had significantly higher odds of being vaccinated against both influenza and pertussis (OR 33.3,
95% CI: 15.15–73.38). Of unvaccinated mothers, 53.6% (95% CI: 45.9–61.3) and 78.3% (95% CI: 70.4–85.3) reported that
they would have been vaccinated against influenza and pertussis, respectively, if their antenatal care provider had
recommended it.
Conclusions: Pertussis vaccination coverage was high in the first year of an antenatal immunisation program in Western
Australia. Despite a substantial increase in influenza vaccination uptake between 2014 and 2015, coverage remained
below that for pertussis. Our data suggest influenza and pertussis vaccination rates of 83% and 94%, respectively, are
achievable if providers were to recommend them to all pregnant women.
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Background
Antenatal influenza vaccination can protect pregnant
women from serious complications of influenza and pre-
vent severe, potentially fatal influenza and pertussis infec-
tions in young infants through maternal antibody transfer
[1]. Vaccinating pregnant women for pertussis during the
third trimester of pregnancy ensures maximum transfer of
maternal antibodies from the vaccine to the child through
the placental membrane, thereby protecting young infants
from the life-threatening complications of pertussis [2, 3].
In Australia, antenatal influenza vaccination has been rec-
ommended to pregnant women at any trimester during
their pregnancy during the flu season and funded through
the national immunisation program since 2010 [4]. Acel-
lular pertussis-diphtheria-tetanus vaccine has been recom-
mended during the third trimester of every pregnancy
since 2015 [5]. The Western Australian (WA) government
has funded provision of antenatal pertussis vaccination
since March 2015, following the death of a one-month old
infant from pertussis [6, 7].
Despite the availability of free vaccine and the demon-
strated effectiveness in pregnant mothers and infants
under 6 months of age [8, 9], previous research has
shown uptake of influenza vaccine during pregnancy to
be sub-optimal [10]. A study in 2014 found that just
41% of pregnant women in WA received influenza vac-
cine during pregnancy [8] with lack of recommendation
of the vaccine from health providers being a main bar-
rier for uptake of the antenatal flu vaccine [10]. More
than 40% of women were not recommended the vaccine
during pregnancy. The majority of women reported that
they would have been vaccinated if a healthcare profes-
sional had recommended the vaccine to them. The study
also found that many women were vaccinated to protect
their unborn child suggesting that promotional efforts
should emphasize on the importance of the vaccine for
the child [10]. A systematic review has also identified
inadequate knowledge of influenza risk and concerns
about the safety of the antenatal influenza as barriers to
uptake [11].
As the introduction of the antenatal pertussis vaccination
program is relatively recent compared to the antenatal in-
fluenza vaccination program, data on pertussis coverage in
Western Australia is limited. However, factors influencing
uptake of the antenatal pertussis vaccine in other Australian
states have been documented. A 2016 survey of 136
Victorian pregnant women found recommendation of the
pertussis vaccine by a health care provider and belief in
protection for the unborn child against pertussis was a
main determinant of vaccine uptake [12]. The importance
of health care provider recommendation was also demon-
strated in surveys of Aboriginal mothers in Western
Australia [13] and women from culturally and linguistic-
ally diverse backgrounds in Melbourne [14].
The aim of this study was to: 1) measure influenza and
pertussis vaccine coverage during pregnancy in the first
year after introduction of an antenatal pertussis vaccin-
ation program; and 2) compare factors associated with
the uptake of each vaccine.
Methods
Annual surveys of antenatal influenza vaccination uptake
have been conducted by the WA Department of Health
(WA DOH) since 2012 [10], and in 2015, this survey was
expanded to include pertussis vaccination. A sample of
women ≥18 years who had given birth to a live infant
between 4th April and 4th October 2015 (i.e. the period
when the 2015 seasonal influenza vaccine was readily avail-
able) were randomly selected from the state’s perinatal birth
dataset; the Midwives Notification System (MNS) is a
mandatory data reporting program that captures > 99% of
all births in the state [15]. Assuming at least 40% uptake of
antenatal vaccines, a final sample of 450 respondents was
required to estimate vaccine coverage with a precision +/−
4.5% at the standard 95% confidence interval. An initial
sample size of 800 women was calculated after taking into
consideration the proportion of women whom could be
contacted by telephone in previous surveys of antenatal in-
fluenza vaccination uptake (~ 60%) and the participation
rate among those contacted (> = 90%). Women selected at
random from the MNS dataset were invited to participate
via a letter sent from WA DOH and given the option to
decline participation. The names and telephone number/s
(as recorded in the MNS) of women who did not ‘opt-out’
were provided to WA DOH interviewers.
Participants were telephoned in December 2015 and
asked to complete a 10-min telephone survey about
whether they had been vaccinated against influenza and/
or pertussis during their last pregnancy, and their reasons
for being vaccinated/unvaccinated. Up to three telephone
calls, at different times of day, were made to each woman;
inability to make contact was recorded as ‘no response’.
At the beginning of the telephone call, verbal consent was
obtained to proceed with the interview and women who
declined were not asked any further questions. Consent or
declination was documented. Women who agreed to be
interviewed were informed that they could cease the inter-
view at any time. Information obtained during the inter-
view included the mother’s age, education level, postcode
of residence, the presence of chronic medical conditions,
and the health care setting where the woman received the
majority of her antenatal care. Because some women re-
ceive paper records of their vaccination, vaccinated
women were asked for the date and batch number of the
vaccine/s for verification purposes. Women who could
not provide the batch number were asked for permission
for WA DOH to retrieve details of the vaccination/s from
their immunisation provider.
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Data analysis
Statistical analyses were performed using SAS version
9.4. To ensure representativeness of survey results, ana-
lyses were weighted by maternal age group and area of
residence. Vaccination uptake of influenza, pertussis and
both vaccines, along with 95% confidence intervals (CIs),
were calculated. Univariate analysis was used to identify
factors associated with vaccination uptake and variables
significant at α = 0.05 were included in a hierarchical
multivariate logistic regression model to control for po-
tential confounding. Reasons for or against influenza or
pertussis vaccination were compared using Pearson’s chi
square analysis. Data from the 2015 antenatal survey
were compared to results of published studies conducted
in a similar manner during 2012–2014 [10, 16, 17].
This study has received written approval from the WA
DOH Human Research Ethics Committee (HREC# 2015/29).
Results
Twenty-three (2.9%) of the 800 randomly selected women
declined to participate in the study after receiving a letter
informing them of their eligibility to participate; of the 777
remaining, 323 (41.6%) could not be contacted via tele-
phone after 3 attempts, 30 (3.9%) declined participation
after being contacted by telephone, and 424 (54.6%) com-
pleted the telephone survey (Fig. 1). Three women (3.9%)
800 adult women who gave birth to a live baby 
between 05/04/2015 and 04/10/2015 were invited for 
interview by letter
WA DOH telephoned 777 
Women to invite them to be 
interviewed
96 women reported receiving no 
vaccine during their pregnancy
325 women reported receiving a
vaccine during their pregnancy
424 women completed 
the interview
Survey data from 421 women 
included in the analysis
320 women gave 
permission to verify 524 
vaccinations
449 
vaccinations 
verified in the 
participant’s 
medical 
record
75 vaccinations could 
not be verified because 
the vaccination provider 
could not be contacted 
or the vaccination could 
not be located in the 
participant’s medical 
record
3 women were unsure whether 
they received a vaccine and 
were excluded from the study
23 women opted out of the 
interview
323 women could not be 
contacted via telephone ;30 
declined participation after 
being contacted by phone
Fig. 1 Participation in a telephone interview about vaccination during pregnancy – Western Australia 2015
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who were unsure whether they had received influenza or
pertussis vaccine were excluded from the analysis.
The majority of survey participants (77.4%) lived in the
Perth metropolitan area (Table 1); this is consistent with
the proportion of births in the state in the Perth area
(79.5%). However, slightly fewer participants were 18–
24 years of age (10.9%) compared to all births during the
study period (15.2%) and mothers 40 years and older were
slightly over-represented (survey: 5.5%; state: 3.7%). Half of
the women received most of their antenatal care at a public
hospital antenatal clinic (49.6%), 30.4% from a private ob-
stetrician, and 16.9% from a general practitioner. One in
ten women (10.5%) had a chronic medical condition and
about a third (31.3%) had a high school education or less.
The proportions of women who reported that their
health care provider recommended that they receive
the influenza, pertussis, or both vaccines, were 74.0%
(95% CI: 69.7–78.3%), 72.4% (95% CI: 68.0–76.7%) and
63.2% (95% CI: 58.5–67.9%), respectively. There were no
differences in the sociodemographic characteristics of
women who were recommended and those who were
not recommended influenza and/or pertussis vaccines
(p > .05). The proportions of women who reported they
had received influenza, pertussis and both influenza and
pertussis vaccinations during their last pregnancy were
60.6% (95% CI: 56.0–65.6%), 71.0% (95% CI: 66.3–75.2%)
and 54.5% (95% CI: 49.7–59.4%), respectively.
Influenza vaccine uptake increased significantly in 2015
with the annual antenatal vaccination survey from 2014
estimating coverage at 42.5% (95% CI: 38.8–46.3%). In
addition, prior to 2015, the majority of women immunised
against seasonal influenza received their vaccination in
the second trimester (range: 54.3% [2013] to 58.9%
[2012]); in 2015, this proportion declined to 28.1% while
the proportion of immunised women who received their
vaccination in the third trimester rose to 55.3% (Fig. 2).
Most (90.1%) women immunised against pertussis re-
ceived the vaccine in their third trimester and of the 211
women who received influenza and pertussis vaccine,
68.2% received both vaccines on the same day.
Of the 320 vaccinated women who gave permission for
their immunisation record/s to be verified against medical
records, 449 (85.7%) of the 524 reported vaccinations were
confirmed (influenza: 79.6%, pertussis: 91.0%).
A total of 66.9% of women reported that they received
their influenza vaccine at a general practice (GP), 17.9%
at a public hospital antenatal clinic and 5.5% at their
workplace; 68.6% of women reported receiving their per-
tussis vaccine at a GP, 20.9% at a public hospital antenatal
clinic and 6.4% at a private hospital clinic.
Predictors of vaccination
On univariate analysis, a healthcare provider’s recom-
mendation (p < .001) was significantly associated with
the uptake of either influenza or pertussis vaccine during
pregnancy (Table 1). The impact of the healthcare pro-
vider’s recommendation on vaccination appears to be
vaccine specific, as women who were recommended per-
tussis vaccine (and not influenza vaccine) had a greater
odds of pertussis (OR: 5.34, 95% CI: 1.23–13.00, p = 0.005)
but not influenza, (OR: 1.56, 95% CI: 0.59–4.09, p = 0.37)
vaccination. Similarly, women who were recommended
influenza vaccine (and not pertussis vaccine) had
greater odds of influenza (OR: 4.47, 95% CI: 1.89–10.59,
p < 0.001) but not pertussis (OR: 0.94, 95% CI: 0.42–2.1,
p = .89) vaccination compared to women not recom-
mended to receive either vaccine. Women whose health-
care provider recommended both antenatal vaccinations
had significantly higher odds of being vaccinated against
both influenza and pertussis (OR 33.3, 95% CI: 15.15–
73.38 p < 0.001). The existence of a chronic medical
condition was negatively associated with pertussis vac-
cine uptake (OR 0.42, 95% CI: 0.22–0.80, p < 0.05)
(Table 1). On multivariate analyses, a healthcare pro-
vider’s recommendation was the only common inde-
pendent predictor of the uptake of influenza, pertussis
and both vaccines (Fig. 3).
Reasons for or against vaccination
Among vaccinated mothers, the most commonly reported
reason they were immunised was to protect the baby
(96.1% of mothers vaccinated against influenza and 98.6%
of those vaccinated against pertussis). A significantly lar-
ger proportion of mothers vaccinated against pertussis vs
influenza reported doing so because of influence of family,
friends and media (73.7% vs 52.1%, p < 0.001) (Table 2).
Commonly reported reasons for not being vaccinated
against pertussis included that vaccination had not been
recommended by an antenatal care provider (43.9%) and
concerns about vaccination harming the baby (23.0%).
Common reasons women did not receive influenza vac-
cine included concerns about side-effects to the mother
(37.1%), harming the baby (32.5%) and because the
vaccine was not recommended by a health provider
(33.6%) (Table 2). Concern about the side effects of the
vaccine were more commonly reported for influenza
vaccine than pertussis vaccine (p = 0.04).
Among unvaccinated women, 53.6% (95% CI: 45.9–61.3)
and 78.3% (95% CI: 70.4–85.3) reported that they would
have been vaccinated against influenza and pertussis, re-
spectively, during their pregnancy if a health care provider
had recommended it.
Discussion
This cross-sectional survey provides the first estimates
of coverage and factors influencing uptake of both ante-
natal pertussis and influenza vaccines in Australia. A
total of 72% of pregnant women received a pertussis
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vaccine; 61% received an influenza vaccine, an increase
from 42% the previous year [16]. These results demon-
strate that most women receive routinely recommended
vaccines during pregnancy in Western Australia, but
there is still room for improvement.
The introduction of the antenatal pertussis vaccination
program in 2015 may have influenced seasonal influenza
vaccination of pregnant women in terms of both uptake and
trimester of vaccine administration. In contrast to previous
years, 2015 was the first year that most women vaccinated
against influenza received the vaccine in their third, rather
than second trimester. As nearly 70% of women who vacci-
nated against both influenza and pertussis received them on
the same day, it would seem that introduction of a recom-
mendation for pertussis vaccination between weeks 28–32 of
pregnancy may have had the effect of shifting the timing of
the influenza vaccination to the third trimester as well as
increasing the coverage of antenatal influenza vaccination.
While vaccinating for influenza during the third trimester of
pregnancy is ideal for antibody transfer [1] to the unborn
child, it leaves pregnant women potentially unprotected
against influenza during their first two trimesters of preg-
nancy. This may have serious adverse consequences for
women at high risk of developing complications of influenza.
WA’s antenatal pertussis vaccination program was quite
successful in its first year, given that in other settings less
than 25% of women received a pertussis vaccine during
pregnancy in the first year of their program [18, 19]. A
recent study from the Northern Territory, Australia, found
that 22.3% of women received a pertussis vaccination dur-
ing pregnancy [18]. In the United Kingdom, the antenatal
pertussis vaccination program was implemented for 4 years
before a comparable coverage of antenatal pertussis vaccin-
ation was achieved (70%) [20]. Unpublished data from the
Fig. 2 Trimester of antenatal influenza vaccination, and proportions of women who had been recommended vaccination and received
vaccination, by year, Western Australia, 2012–2015
Fig. 3 Multivariate logistic regression analysis of factors affecting antenatal pertussis and/or influenza uptake in Western Australia in 2015
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WA Department of Health indicates that antenatal pertus-
sis coverage in WA has not only been sustained, but has
continued to increase to almost 80% in 2016.
One factor which may have influenced this success
in WA is the potential influence of the tragic death of
a young infant in early March 2015. At that time the
mother was pregnant, antenatal pertussis vaccination
was not recommended in the Australian Immunisa-
tion Handbook and there was no government-funded
pertussis vaccination program in WA in place [21].
The baby’s death was well publicised and his family
continue to promote the benefits of antenatal and
childhood vaccination in Australia via mass- and
social-media and parent and baby expos. The impact
of their efforts is likely reflected in the high propor-
tion of mothers who said they were vaccinated against
pertussis because of the influence of family, friends and
media (74%). This finding suggests that social-media and
community-driven campaigns can be effective in promot-
ing vaccinations among pregnant women.
Despite the success of WA’s antenatal pertussis vaccin-
ation program and continued increases in antenatal influ-
enza uptake, further improvement in uptake is achievable
and should be pursued. Results from this survey and other
studies have consistently identified the recommendation by
a healthcare provider as the strongest predictor of antenatal
vaccination [12–14, 16–18]. Although influenza and pertus-
sis vaccination were standard antenatal care for women in
our study, less than two-thirds were recommended both
vaccines during their pregnancy. Data from unvaccinated
women in this survey suggest that if 100% of women were
recommended to be vaccinated in accordance with current
standard-of-care obstetrical guidelines in Australia, cover-
age rates among pregnant women for influenza and pertus-
sis vaccine could reach 82% and 94%, respectively.
Barriers to vaccination reported by the women in this
survey reveal a need for additional education for pregnant
mothers and their antenatal care providers. Over a third
of women not vaccinated for influenza and 27% of women
not vaccinated for pertussis cited concerns about side
Table 2 Reasons why women received/did not receive an influenza or pertussis vaccination – Western Australia, 2015
(multiple responses allowed)
Reasons why vaccinated women received a vaccine during pregnancy Influenza vaccine (n = 256) Pertussis vaccine (n = 299) p-value
n (%) n (%)
Protect baby 247 (96.1) 296 (98.6) .30
Influenced by family, friends and media 136 (52.1) 222 (73.7) <.001
Antenatal care provider recommended it 229 (90.6) 265 (88.4) .48
General practitioner recommended it 155 (61.3) 172 (57.9) .83
Worried about pertussis/influenza 138 (53.7) 188 (63.2) .03
Obstetrician recommended it 129 (49.1) 157 (52.4) .25
Midwife recommended it 128 (49.6) 165 (55.9) .02
To protect family 6 (2.2) – –
To protect herself 11 (4.2) – –
Normally get vaccine 115 (44.6) – –
Health care employee 8 (2.9) – –
Chronic medical condition 16 (6.4) – –
Reasons why unvaccinated women did not receive a vaccine during pregnancy Influenza vaccine (n = 165) Pertussis vaccine (n = 122) p-value
n (%) n (%)
No antenatal care provider recommendation 56 (33.6) 54 (43.9) .64
Worried that it would harm the baby 54 (32.5) 28 (23.0) .47
Worried about potential side effects 62 (37.1) 15 (11.9) .04
Was advised against it 11 (6.9) 8 (7.8) .92
Was too late in pregnancy – 7 (5.9) –
Vaccine not available 6 (3.7) 3 (2.5) .58
Already received or planning to receive after pregnancy 7 (6.9) 11 (8.6) .10
Not necessary 6 (3.4) – –
Don’t normally get vaccine 56 (33.3) – –
First trimester of pregnancy 43 (25.8) – –
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effects of the vaccination to themselves or harm to their
babies as reasons for non-vaccination. Other reasons re-
ported for not vaccinating include already being immu-
nised for pertussis before pregnancy and/or plans to
vaccinate post-partum. None of these reasons for not be-
ing vaccinated in pregnancy are evidence-based decisions
[3, 8, 10, 22]. The results also suggest that further educa-
tion would be beneficial for antenatal care providers given
that 8% and 7% of women not vaccinated for pertussis
and influenza respectively reported that a healthcare pro-
vider had advised them against vaccination.
A negative association between having a chronic med-
ical condition and pertussis vaccination uptake even
after controlling for healthcare provider’s recommenda-
tion was unexpected. It is not clear why women with a
chronic medical condition would be more likely than
women without a chronic medical condition to refuse
pertussis vaccination if it was offered.
There are several limitations to our study. First, assign-
ment of vaccination status relied on self-report. Previous
research has shown that vaccination coverage can be
over-estimated based on self-report [23]. However, we were
able to verify 86% of self-reported vaccinations directly with
the immunisation provider, suggesting any bias introduced
is likely to be small. Second, although women were selected
at random to participate in the survey, there was some
under-representation of mothers under the age of 25 years.
To account for this under-representation, survey results
were weighted by age and apart from this particular subset
of women, age and geographic distribution of survey re-
spondents was generally comparable with the population of
women eligible for study selection. The response rate of
54.6% is considered satisfactory for a telephone survey [24].
Finally, this survey was conducted in WA and the views
and opinions of mothers in this state may not represent
those in other parts of Australia or other countries. Further
assessments on the uptake of pertussis and influenza
vaccines in other geographic settings are needed.
Conclusions
Almost three-quarters of pregnant women were immu-
nised in the first year of an antenatal pertussis vaccination
program. Although increasing, antenatal influenza vaccine
coverage remains lower than that for pertussis vaccine. A
substantial proportion of unimmunised women indicated
that they would have been vaccinated if it had been rec-
ommended to them by an antenatal care provider, sug-
gesting that antenatal vaccination coverage approaching
90% could be achieved if providers universally recom-
mended immunisation. Strategies for improving ante-
natal vaccination uptake should include education of
pregnant women and their healthcare providers on the
benefits and safety of influenza and pertussis vaccin-
ation during pregnancy.
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